Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Development of a Standardized Interoperability System Between Electronic Health Records and REDCap.

Studies in health technology and informatics·2026
Same author

Validation of a patient-based strategy for ambulatory monitoring of oncological pain by a mobile application.

Scientific reports·2026
Same author

Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose-lowering drugs with machine learning-The Maastricht study.

Diabetes, obesity & metabolism·2025
Same author

Roadmap to Innovation of HTA Methods (IHTAM): insights from three case studies of quantitative methods.

International journal of technology assessment in health care·2024
Same author

Cluster analysis of adult individuals with type 1 diabetes: Treatment pathways and complications over a five-year follow-up period.

Diabetes research and clinical practice·2024
Same author

Precision nutrition impact on metabolic health and quality of life in aging population after a 3-month intervention: A randomized intervention.

The journal of nutrition, health & aging·2024

Related Experiment Videos

Interpretable deep learning to predict one year glycemic control in type 1 diabetes using real world data.

Jose Tapia-Galisteo1,2, Francisco Javier Somolinos-Simón1, M Elena Hernando1,2,3

  • 1Bioengineering and Telemedicine Group, Centro de Tecnología Biomédica, ETSI de Telecomunicación, Universidad Politécnica de Madrid, Avd. Complutense 30, 28040, Madrid, Spain.

Scientific Reports
|July 4, 2026
PubMed
Summary

This study developed a deep learning model to predict 1-year glycemic control in Type 1 diabetes (T1D) patients. The interpretable model aids clinicians in personalizing T1D treatment and improving patient outcomes.

Keywords:
CalibrationDeep learningDiabetesDiscriminationGlycemic control predictionInterpretability

Related Experiment Videos

Area of Science:

  • Endocrinology and Metabolism
  • Artificial Intelligence in Healthcare
  • Clinical Data Science

Background:

  • Type 1 diabetes (T1D) presents long-term health risks and challenges in therapeutic individualization.
  • Achieving glycemic targets is crucial for effective diabetes management and prognosis.
  • Real-world data (RWD) offers opportunities for predictive modeling in T1D.

Purpose of the Study:

  • To develop a clinically interpretable predictive model for 1-year glycemic control in T1D patients using RWD.
  • To evaluate Deep Learning techniques for predicting glycemic control and assess model performance.
  • To enhance clinical decision-making through an interpretable risk prediction tool.

Main Methods:

  • Utilized RWD from 8999 T1D patients to build a predictive model for binary glycemic control (HbA1c-based).
  • Compared various Deep Learning models, feature subsets, calibration techniques (e.g., scaling-binning), and sampling strategies.
  • Developed a graphical representation for model interpretability, quantifying variable contributions to risk scores.

Main Results:

  • The best model, using 12 features (socio-demographics, clinical variables, complications, medications), achieved an AUC of 0.870 and F1-score of 0.789.
  • Scaling-binning calibration demonstrated superior performance.
  • Interpretable graphical outputs quantified individual variable impact on predicted risk.

Conclusions:

  • The developed Deep Learning model offers high accuracy, calibration, and interpretability for predicting T1D glycemic control.
  • This tool can assist clinicians in making individualized treatment decisions and intensifying care for high-risk patients.
  • The model supports optimized healthcare resource allocation and proactive T1D management.